Shares of Enfusion, Inc. (NYSE:ENFN – Get Free Report) saw strong trading volume on Thursday . 1,375,855 shares were traded during mid-day trading, an increase of 2% from the previous session’s volume of 1,346,222 shares.The stock last traded at $10.96 and had previously closed at $10.92.
Analysts Set New Price Targets
ENFN has been the topic of a number of recent analyst reports. Piper Sandler boosted their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Stifel Nicolaus increased their price target on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $10.25.
Check Out Our Latest Stock Report on ENFN
Enfusion Stock Up 0.9 %
Insiders Place Their Bets
In related news, CEO Oleg Movchan sold 2,771 shares of Enfusion stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at $11,469,746.32. This trade represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,041 shares of company stock worth $597,367. Insiders own 36.44% of the company’s stock.
Hedge Funds Weigh In On Enfusion
A number of hedge funds and other institutional investors have recently made changes to their positions in ENFN. Bank of New York Mellon Corp raised its position in Enfusion by 29.4% in the second quarter. Bank of New York Mellon Corp now owns 159,555 shares of the company’s stock worth $1,359,000 after acquiring an additional 36,257 shares during the period. Rhumbline Advisers raised its holdings in shares of Enfusion by 30.3% in the 2nd quarter. Rhumbline Advisers now owns 59,435 shares of the company’s stock worth $506,000 after purchasing an additional 13,832 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Enfusion in the 2nd quarter worth approximately $183,000. American Century Companies Inc. lifted its stake in Enfusion by 17.1% in the second quarter. American Century Companies Inc. now owns 35,897 shares of the company’s stock valued at $306,000 after purchasing an additional 5,253 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Enfusion by 57.5% during the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares during the period. 81.05% of the stock is owned by hedge funds and other institutional investors.
About Enfusion
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Further Reading
- Five stocks we like better than Enfusion
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Stock Dividend Cuts Happen Are You Ready?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Top Biotech Stocks: Exploring Innovation Opportunities
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.